Time Course of Axon and Myelin Degeneration in Peripheral Nerves in Experimental Autoimmune Neuritis Rats.


Journal

Toxicologic pathology
ISSN: 1533-1601
Titre abrégé: Toxicol Pathol
Pays: United States
ID NLM: 7905907

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 17 4 2019
medline: 29 1 2020
entrez: 17 4 2019
Statut: ppublish

Résumé

Experimental autoimmune neuritis (EAN) is an animal model for Guillain-Barré syndrome (GBS), which results in neurological symptoms and histopathological changes in peripheral nerves. In this model, the correlation between the progression of the disease and the histopathological changes is not clear. To further examine histopathological changes in peripheral nerves in EAN rats, sciatic nerves were sampled at onset (day 10), peak (day 16), and recovery (days 22 and 25) of neurological symptoms in P2(57-81)-peptide-administered rats. Axon and myelin degeneration was observed by light microscopy at onset, degeneration became severe at peak, and persisted at recovery. Densities of myelinated nerve fibers and myelin areas decreased from day 10 to a minimum on day 22. Slight axon and myelin degeneration, such as accumulation of vesicles in axons and focal myelin splitting and folding, was observed by transmission electron microscopy at onset; severe degeneration, such as axonal loss, myelin ovoid, and demyelination, increased at peak; and regenerative changes, such as remyelination and enlargement of Schwann cell cytoplasm, occurred at recovery. These results suggest that EAN rats have histopathological similarities to some types of GBS patients and that EAN rats are a useful model to understand the pathogenesis of GBS.

Identifiants

pubmed: 30987532
doi: 10.1177/0192623319838993
doi:

Substances chimiques

Myelin P2 Protein 0
Peptide Fragments 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

542-552

Auteurs

Emi Tomikawa (E)

1 Pharmaceutical Research Laboratories, Toray Industries, Inc., Kanagawa, Japan.

Mayu Mutsuga (M)

1 Pharmaceutical Research Laboratories, Toray Industries, Inc., Kanagawa, Japan.

Kojiro Hara (K)

1 Pharmaceutical Research Laboratories, Toray Industries, Inc., Kanagawa, Japan.

Chihiro Kaneko (C)

1 Pharmaceutical Research Laboratories, Toray Industries, Inc., Kanagawa, Japan.

Yuko Togashi (Y)

1 Pharmaceutical Research Laboratories, Toray Industries, Inc., Kanagawa, Japan.

Yohei Miyamoto (Y)

2 Clinical Research Department, Toray Industries, Inc., Tokyo, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH